Heyholder
‹ Activism Filings

Onconic Therapeutics Inc. Q3 operating loss of KRW 4.3 billion on KRW 17.0 billion revenue (standalone)

Onconic Therapeutics Inc.· Periodic Report

AI summary · Not investment advice

Oncotic Therapeutics sold KRW 17.0 billion in the third quarter but lost KRW 4.3 billion from its main business, down from a profit a year earlier.

Operating profit · 3 months

KRW -4.3 billion

Key facts

Revenue (3 months)
KRW 17.0 billion
Net income (3 months)
KRW -7.7 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 19.2 billion
Revenue (year to date)
KRW 64.4 billion
Operating profit (prior-year 3 months)
KRW 8.3 billion
Operating profit (year to date)
KRW 3.0 billion
Net income (prior-year 3 months)
KRW 9.4 billion
Net income (year to date)
KRW 2.5 billion

Commentary

AI commentary · Not investment advice

What happened

Onconic Therapeutics filed its quarterly report with standalone results for the third quarter of 2026.

In the company's terms

Sales for the 3 months were KRW 17.02 billion, down 11.4% from KRW 19.21 billion a year earlier.

What changes for shareholders

Operating profit (profit from the core business) was a loss of KRW 4.35 billion. A year earlier it was a profit of KRW 8.32 billion. It also turned to a loss compared with the previous quarter.

Net income (final profit after taxes and other items) was a loss of KRW 7.69 billion. A year earlier it was a profit of KRW 9.40 billion.

For the cumulative period from January to September, sales were KRW 64.40 billion. Operating profit was KRW 3.03 billion. Net income was KRW 2.50 billion. Both remain profits on a cumulative basis.

Comments

No comments yet

Comments from shareholders will appear here.